Boston Partners Grows Position in Enovis Corporation $ENOV

Boston Partners grew its stake in shares of Enovis Corporation (NYSE:ENOV) by 42.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,382,724 shares of the company’s stock after purchasing an additional 411,744 shares during the period. Boston Partners owned approximately 2.42% of Enovis worth $43,352,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. T. Rowe Price Investment Management Inc. increased its holdings in shares of Enovis by 0.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 6,207,768 shares of the company’s stock valued at $237,199,000 after purchasing an additional 44,632 shares in the last quarter. Vanguard Group Inc. grew its position in Enovis by 11.3% during the first quarter. Vanguard Group Inc. now owns 6,107,199 shares of the company’s stock worth $233,356,000 after buying an additional 621,069 shares during the period. Dimensional Fund Advisors LP increased its holdings in Enovis by 1.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,927,340 shares of the company’s stock valued at $111,852,000 after buying an additional 27,894 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Enovis by 43.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,342,481 shares of the company’s stock valued at $42,105,000 after acquiring an additional 408,608 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Enovis by 191.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 810,771 shares of the company’s stock valued at $26,772,000 after acquiring an additional 532,648 shares during the period. 98.45% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Enovis news, CEO Damien Mcdonald bought 6,457 shares of Enovis stock in a transaction that occurred on Thursday, September 11th. The shares were purchased at an average cost of $30.97 per share, for a total transaction of $199,973.29. Following the completion of the transaction, the chief executive officer owned 102,753 shares of the company’s stock, valued at $3,182,260.41. This represents a 6.71% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.70% of the company’s stock.

Enovis Stock Performance

Shares of ENOV opened at $30.32 on Friday. Enovis Corporation has a 1 year low of $25.47 and a 1 year high of $49.75. The company’s 50 day simple moving average is $30.74 and its 200 day simple moving average is $31.02. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of -2.13 and a beta of 1.67. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.15 and a current ratio of 2.25.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Monday, January 8th. The company reported $0.59 earnings per share for the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The company had revenue of $383.81 million during the quarter. On average, sell-side analysts predict that Enovis Corporation will post 2.79 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. UBS Group dropped their price target on Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Needham & Company LLC decreased their price objective on shares of Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Wells Fargo & Company raised their target price on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, Canaccord Genuity Group cut their target price on shares of Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $51.17.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.